Key result
OSA-COPD overlap syndrome linked to ~21% higher in-hospital mortality versus OSA alone after PCI.
Why the study?
The impact of COPD and obesity hypoventilation syndrome in OSA patients undergoing PCI had never been studied.
Does the presence of concomitant COPD or obesity hypoventilation syndrome worsen clinical outcomes in patients with obstructive sleep apnea undergoing PCI?
Observational (n=4,792,177)
Yes
Does the presence of concomitant COPD or obesity hypoventilation syndrome worsen clinical outcomes in patients with obstructive sleep apnea undergoing PCI?
Concomitant obesity hypoventilation syndrome or COPD significantly increases the risk of in-hospital mortality, complications, and resource utilization in patients with obstructive sleep apnea undergoing PCI.
Answers are grounded in this paper and cite their sources.
May warrant heightened periprocedural vigilance in OSA patients with COPD or obesity hypoventilation syndrome undergoing PCI; leaves open whether interventions modify outcomes.
Background Obstructive sleep apnea (OSA) is often present in coronary artery disease patients and confers a high risk of complications following percutaneous coronary interventions (PCI). The impact of two commonly associated comorbid conditions, chronic obstructive pulmonary disease (COPD) and obesity hypoventilation syndrome (OHS, Pickwickian syndrome) in OSA patients undergoing PCI has never been studied. Methods The National Inpatient Sample (NIS; 2007-2014) was queried using the International Classification of Diseases, Clinical Modification 9 (ICD-9-CM) codes to compare baseline characteristics, comorbidities, and outcomes in adults undergoing PCI with OSA, COPD-overlap syndrome, and OSA+OHS. Results Of a total of 4,792,177 PCI-related inpatient encounters, OSA, OSA-COPD overlap syndrome, and OSA+OHS were found to be present in 153,706 (median age 62 years, 79.4% male), 65135 (median age 65 years, 66.0% male), and 2291 (median age 63 years, 58.2% males) patients, respectively. The OHS+OSA cohort, when compared to the COPD-OSA and OSA cohorts, was found to have the worst outcomes in terms of all-cause mortality (2.8% vs. 1.5% vs. 1.1%), hospital stay (median 6 vs. 3 vs. 2 days), hospital charges ($147, 209 vs. $101,416 vs. $87,983). Complications, including cardiogenic shock (7.3% vs. 3.4% vs. 2.6%), post-procedural myocardial infarction (11.2% vs. 7.1% vs. 6.0%), iatrogenic cardiac complications (6.1% vs. 3.5% vs. 3.7%), respiratory failure, acute kidney injury, infections, and pulmonary embolism, were also significantly higher in patients with OHS+OSA. Adjusted multivariable analysis revealed equivalent results with OHS+OSA having worse outcomes than OSA-COPD and OSA. Conclusion Concomitant OHS and COPD were linked to worse clinical outcomes in patients with OSA undergoing PCI. Future prospective studies are warranted to fully understand related pathophysiology, evaluate and validate long-term outcomes, and formulate effective preventive and management strategies.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2022) conducted an observational in Percutaneous coronary intervention with obstructive sleep apnea (n=4,792,177). OSA-COPD overlap syndrome vs. OSA alone was evaluated on All-cause in-hospital mortality (OR 1.21, 95% CI 1.11-1.32, p=<0.001). In patients undergoing percutaneous coronary intervention, concomitant OSA-COPD overlap syndrome increased the odds of in-hospital mortality compared to OSA alone, and OSA with obesity hypoventilation syndrome was associated with the highest unadjusted mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: